![](https://www.smileagents.com/wp-content/uploads/2024/03/NEOPUTTY-1.jpg)
![](https://www.smileagents.com/wp-content/uploads/2024/03/NEOSEALER-WITH-FLEX-FLO-TIP-1-600x518.png)
Avalon Biomed NeoMTA2 2.5GM Kit
350.00 ر.س – 550.00 ر.س
Product Options
NeoMTA2 is a stainproof bioactive bioceramic cement that is used universally for vital pulp therapy in primary and permanent teeth. The active ingredient, a blend of tricalcium silicate and dicalcium silicate, triggers the healing process by forming hydroxyapatite on its surface. MTAs are the only vital pulp therapy medicaments that have been proven to be more effective than calcium hydroxide, and as effective as formocresol, for primary tooth vital pulp therapy. The AAPD GUIDELINES ON PULP THERAPY FOR PRIMARY/IMMATURE PERMANENT TEETH recommend MTA for a variety of pediatric vital pulp therapy indications including pulp capping, pulpotomy, apexification.
Indications
- Direct pulp capping
- Partial pulpotomy
- Pulpotomy and apecogenesis
- Root resorption
- Root apexification
- Indirect pulp capping
- Cavity liner and base
- Perforation repair
- Obturation
- Root-end filling
Features & Benefits
Bioactive Bioceramic
- Promotes the formation of hydroxyapatite on the surface to seal and support healing through the release calcium and hydroxide ions.
- Biocompatible, Non-cytotoxic, Non-genotoxic, initially high in pH (alkaline/basic), which has shown to be antimicrobial in-vitro1.
Resin-Free
- Dimensionally stable with no shrinkage to ensure a gap-free seal, minimizing opportunity for bacterial infiltration.
- Resin-free for maximum bioactivity.
Easier to Mix
- Our improved gel formula allows for an easier mixing process.
30% Higher Radiopacity
- 6.5 mm AI equivalent radiopacity when mixed to a firm putty.
Brighter whiteNon-Staining
- Won’t discolor teeth – EVER. NaOCI won’t cause discoloration.
3-year shelf life
Package Size |
Avalon Biomed NeoMTA 2. 2.5gm Professional Kit, Avalon Biomed NeoMTA2 1 gm Kit |
---|
You must be logged in to post a review.
Reviews
There are no reviews yet.